Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
內克塔治療2024Q2 GAAP每股收益爲$(0.25)，未達到$(0.21)的預計值，銷售額爲2348.9萬美元，超過1754.5萬美元的預計值。
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $23.489 million which beat the analyst consensus estimate of $17.545 million by 33.88 percent. This is a 14.59 percent increase over sales of $20.499 million the same period last year.
內克塔治療（納斯達克：NKTR）每股虧損0.25美元，比分析師共識預估的0.21美元少19.05%。該公司季度銷售額爲2348.9萬美元，比分析師共識預估的1754.5萬美元高33.88%。這是去年同期銷售額2049.9萬美元的14.59%增長。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。